Description:Cis-Atovaquone is an antiprotozoal and antifungal agent primarily used in the treatment of Pneumocystis pneumonia and certain types of malaria. It is a member of the naphthoquinone class of compounds, characterized by its unique cis configuration, which influences its biological activity and solubility. The molecular structure features a naphthalene ring system with various functional groups that contribute to its pharmacological properties. Cis-Atovaquone exhibits a high affinity for mitochondrial electron transport, disrupting the energy metabolism of susceptible organisms. It is typically administered orally and is known for its relatively low toxicity profile compared to other antimalarial drugs. The compound is lipophilic, which affects its absorption and distribution in the body. Additionally, it has been studied for its potential in treating other parasitic infections and certain cancers, highlighting its versatility in medicinal chemistry. As with any pharmaceutical agent, its use should be guided by clinical considerations and potential side effects.
We use cookies to enhance your visit. We do not include advertising.
Please see our Cookies Policy for more details or adjust your preferences in "Settings".
This is the advanced settings system for our own and third-party cookies. Here you can modify parameters that will directly affect your browsing experience on this website. If you wish you may check the list of Cookie types.
Please note that disabling cookies can cause failures in the normal operation of the web.
